Dr. Hemminki has authored nearly 400 peer-reviewed manuscripts or book chapters on cancer research and oncolytic viruses.
Some recent notable examples of scientific publications include:
- Phase I ovarian cancer trial with TILT-123 and anti-PD-1 (NCT05271318)
- Effective intravenous delivery of TILT-123 in three phase I trials
- Complete response in mucosal melanoma patient with TILT-123
- Phase I melanoma trial with TILT-123 and ACT TIL therapy (NCT04217473)
- Phase I monotherapy clinical trial with TILT-123 biomarker study
- Phase I monotherapy clinical trial with TILT-123 (NCT04695327)
- Effective intravenous delivery of TILT-123 with anti-PD-1 (preclinical)
- TILT-123 Mechanism of Action (preclinical)
- TILT-123 combined with ACT TIL therapy (preclinical)
- TILT-123 combined with CAR T-cell Therapy (preclinical)
- TILT-123 Seminal paper (preclinical)
- Activity in ovarian cancer patients with TILT-123 prototype
